The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus
NCT00154479 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 700
Last updated 2006-12-14
Summary
Cervical cancer is the most frequent neoplasm of women in Taiwan and in the world. It influences about 2,700 women with about 1,000 women dying of cervical cancer each year and in Taiwan. Human papillomaviruses (HPV) have been consistently implicated in causing cervical cancer especially those high-risk types which have been strongly associated with cervical cancer. In recent years, there has been compelling evidence that infection with human papillomavirus (HPV) is a major etiologic factor in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.
As in most virus-induced diseases, an adequate immune response is likely to play a key role in the clearance of HPV infections and HPV-related lesions. This assumption is born out by both epidemiological studies and animal models. Immune-compromised patients such as HIV-infected women, organ transplant recipients, and patients suffering from other forms of malignancies, are at a higher risk of developing CIN lesions and invasive cervical cancer. Moreover, several studies establish the existence of natural HPV E7-specific cytotoxic T lymphocyte (CTL) immunity in humans. Only a minority of women infected with oncogenic HPV types develop CIN or cervical cancer. Indeed, the majority of CIN lesions do not progress or even regress to normal cytology, indicating that other factors such as an inadequate immune function are necessary for the development of progressive CIN lesions and cervical carcinoma.
Consequently, the HLA class I and II phenotypes may be correlated with an effective immune response against HPV-associated cervical lesions. Differences in the recognition of foreign antigens, such as those contributed by alleles at the HLA class I or II loci, might be proposed to affect the risk of developing cervical cancer.
In the present proposal, the investigators would like to examine the HLA class I and II associations among Taiwanese women with cervical neoplasia. The purposes of this proposal are:
1. to address the relationships between the HLA class I and II haplotype, HPV infection, and cervical cancer; and
2. to elucidate the immunologic responses to HPV type 16 in different HLA class I and II haplotypes. It will help the investigators to identify which population of HLA genotypes is more susceptible to HPV infection and progresses to invasive cervical cancer. The results of this research will be very useful for the prevention and screening of cervical cancer in the future.
Conditions
- Cancer of Cervix
Sponsors & Collaborators
-
National Taiwan University Hospital
lead OTHER
Principal Investigators
-
Wen-Fang Cheng, MD, PhD · National Taiwan University Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2003-10-31
- Completion
- 2008-12-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Evaluation of ELISA Assay on Human Papilloma Viruses (HPV) Infection Population
NCT00673192 ·Status: UNKNOWN ·Phase: NA
-
The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis
NCT00728871 ·Status: UNKNOWN ·Phase: NA
-
A Multi-center Survey of HPV in Cervical Intraepithelial Neoplasia (CIN) With Longitudinal Follow-up of LSIL Cases
NCT00201370 ·Status: COMPLETED
-
Comparison of Human Papillomavirus Integrated DNA and Messenger RNA in Cervical Neoplasia
NCT02198365 ·Status: COMPLETED
-
Cross-sectional Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Cervical Cancer
NCT01221987 ·Status: COMPLETED
-
Improving Cervical Cancer Screening Among HIV-Infected Women in India
NCT02247999 ·Status: COMPLETED
-
The Correlation Between Tumor Angiogenesis and the Effect of Radiation Therapy in Cervical Cancer Patients
NCT00155077 ·Status: UNKNOWN
-
Characterization of Immunosuppressive Signing of Cervical Cancer
NCT02875990 ·Status: UNKNOWN ·Phase: NA
-
The Predictive Role of HPV Integration in HSIL and Cervical Cancer
NCT05300243 ·Status: UNKNOWN
-
Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia
NCT04274465 ·Status: COMPLETED
-
Construction and Validation of a Diagnostic Model for Predicting Molecular Residual Disease and Recurrence of Cervical Cancer Based on Circulating Tumor HPV
NCT06456112 ·Status: NOT_YET_RECRUITING
-
The Association of G9a Protein and the Outcome of Patients With Cervical Cancer
NCT01505751 ·Status: COMPLETED
-
Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT Therapy
NCT04951921 ·Status: COMPLETED ·Phase: PHASE2
-
Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV
NCT04974424 ·Status: UNKNOWN
-
Prognostic Study of HPV Virus Integration in Women With HSIL
NCT05745597 ·Status: RECRUITING
-
Knowledge, Attitude &practice on Human Papilloma Virus Vaccination Among Healthcare Providers and General Population
NCT06743880 ·Status: NOT_YET_RECRUITING
-
102 Annual Pap Smear Screening Database Maintenance Project
NCT02063152 ·Status: UNKNOWN
-
Screening and Identification of Ovarian Cancers
NCT00854399 ·Status: UNKNOWN ·Phase: NA
-
HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer
NCT01984359 ·Status: COMPLETED ·Phase: NA
-
Improving Detection and Early Action for HPV-positive Oropharynx Cancer
NCT04871490 ·Status: COMPLETED ·Phase: NA
-
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
NCT04574635 ·Status: ACTIVE_NOT_RECRUITING
-
Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment
NCT04743674 ·Status: RECRUITING
-
Multiple Human Papillomavirus Infections in the Development of CIN
NCT06862102 ·Status: RECRUITING
-
HPV Infections, Cancer of the Vulva and Therapeutical Success
NCT03082950 ·Status: COMPLETED
-
Clinical Evaluation of Detection of High Risk HPV in Urine
NCT05210348 ·Status: UNKNOWN